@FierceBiotech: Honeybee substance freezes prostate cancer growth (Hint: it's not honey). More | Follow @FierceBiotech
@RyanMFierce: Talon takes it in the teeth, back to penny stock, after FDA says more time needed to review lead cancer drug. Article | Follow @RyanMFierce
> San Diego-based Celladon has brought in $53 million through a second close of a financing round that was initially announced earlier this year. Item
> Vaccine developer Intercell, based in Austria, has struck a deal with Swiss firm BB Biotech as part of its plans to raise $26.1 million to sure up its financial position. Report
> In a deal that includes pre-commercialization fees of $3 million, Pozen ($POZN) has licensed certain European rights to its migraine treatment to Desitin Arzneimittel. Item
@FiercePharma: Some Revlimid patients at higher risk of other blood cancers compared w/ placebo, FDA says--Story. | Follow @FiercePharma
> Docs riled by FDA's proposal to open up drug access. More
> Europe may be austere, but it's also hiring in pharma. Story
> Novartis may weigh Lucentis price cut in U.K. Article
> Abbott to pay $1.6B to wrap up Depakote marketing probe. News
Medical Devices News
@FierceMedDev: Baxter is facing an SEC subpoena for records of its 2010 pump recall. More | Follow @FierceMedDev
> Boston Scientific's CEO: CRM business in active rebuilding mode. Article
> Canada's Monteris snags $9M in investments for NeuroBlate. News
> Dutch test boosts prospects for photoacoustic breast imaging device. Story
> Allergan subpoenaed over Lap-Band obesity device. More
Pharma Manufacturing News
> Baxter bitten again by problems with Colleague infusion pumps. News
> Pfizer to grow manufacturing capacity in Indonesia. Article
> Sanofi closing plant in Missouri, 4 years later than expected. More
> BASF erecting 50,000-ton-plus formic acid plant in Louisiana. Story
Biotech Research News
> Researchers find key to premature aging syndrome. Spotlight
> Controversial bird flu study details revealed. Article
> Stem cells grown from skin treat muscular dystrophy in mice. News
> Stem cell/gene therapy holds HIV at bay in mouse trials. More
And Finally… Retrophin, a biotech startup focused on rare-disease treatments, has raised $4 million in a Series A round led by MSMB Capital. Release